Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Synaptic, Merck deal

MRK relinquished its 1993 exclusive license to SNAP's alpha-adrenergic

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE